Gilead Sciences | 应收帐款人



Trade Debtors 更改 日
AbbVie USD 10.92B 553M 2024-12
Agios Pharmaceuticals USD 4.11M 991K 2024-12
ALKERMES USD 394.72M 24.54M 2024-12
Alnylam Pharmaceuticals USD 405.31M 51.46M 2024-12
Amgen USD 6.78B 535M 2024-12
Biogen USD 1.87B 119.3M 2024-12
BioMarin Pharmaceutical USD 660.54M 117.01M 2024-12
Bristol-Myers Squibb USD 14.42B 471M 2024-12
Eli Lilly USD 13.28B 1.22B 2024-12
Gilead Sciences USD 4.42B 167M 2024-12
GlaxoSmithKline GBP 7.32B 542M 2024-12
Glaxosmithkline GBP 7.32B 542M 2024-12
Incyte USD 853.15M 94.7M 2024-12
J&J USD 14.84B 1.33B 2024-12
Merck USD 11.12B 1.06B 2024-12
Moderna USD 592M 1.24B 2024-12
Neurocrine Biosciences USD 479.1M 2M 2024-12
Novartis USD 9B 854M 2024-12
Pfizer USD 14.78B 2.92B 2024-12
PTC Therapeutics USD 158.55M 41.42M 2024-12
Regeneron Pharmaceuticals USD 6.21B 6B 2024-12
Sanofi 8.8B 2.24B 2024-06
Sarepta Therapeutics USD 649.73M 133.74M 2024-12
United Therapeutics USD 279.3M 62.5M 2024-12
Vertex Pharmaceuticals USD 1.61B 141.2M 2024-12



Gilead Sciences 应收帐款人 - 当前值，历史数据，预测，统计，图表和经济日历 - Mar 2025.